Innovative therapeutic approaches for the 2019-novel coronavirus [supplements: COVID-19 Variant Network, COVID-19 Variant Supplement, sex as a biological variable supplement]
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 170629, 175564, 175494, 171486
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$779,937Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
PendingResearch Location
CanadaLead Research Institution
CHU de QuébecResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Subject
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The 2019-novel coronavirus (SARS CoV-2) is a major sanitary and economical threat to all countries. Development of effective antivirals is a major global priority especially early in the epidemic when vaccines are unavailable. This proposal aims at discovering and evaluating active compounds by rational design through 3D modeling of key viral proteins and also by analyzing cellular gene signatures induced by the virus. In-depth evaluation of selected compounds will include in vitro, ex vivo (human bronchial epithelium tissues) and in vivo (animal models) studies. These approaches, mostly based on drug repurposing (new indication for an existing drug), will result in rapid identification of anti-SARS CoV-2 compounds with accelerated clinical development.